Madhu Kumar
Stock Analyst at Goldman Sachs
(2.87)
# 1,595
Out of 5,116 analysts
145
Total ratings
56.44%
Success rate
20.34%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $164.49 | +12.47% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $10.73 | -44.08% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $10.54 | +61.29% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.89 | +111.64% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $279.24 | -44.49% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $63.19 | -16.13% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $10.21 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $69.33 | +5.29% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $22.58 | +524.45% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $20.31 | +67.41% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.55 | +135.29% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $7.47 | +87.42% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $15.49 | +35.62% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $28.16 | -82.24% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $1.99 | +302.01% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $13.38 | +565.17% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $11.50 | +943.48% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.10 | +9,627.63% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $13.15 | +546.39% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $3.79 | +929.02% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $22.72 | +150.88% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.13 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $0.80 | +112,965.33% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $7.44 | +168.82% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.23 | +42,525.75% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $44.34 | -21.06% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $13.52 | +195.86% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $25.78 | +1,855.38% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $338.06 | -31.96% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $9.59 | +11,630.97% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.88 | +4,434.63% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $29.43 | -26.95% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $49.96 | -52.96% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $164.49
Upside: +12.47%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $10.73
Upside: -44.08%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $10.54
Upside: +61.29%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.89
Upside: +111.64%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $279.24
Upside: -44.49%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $63.19
Upside: -16.13%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $10.21
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $69.33
Upside: +5.29%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $22.58
Upside: +524.45%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $20.31
Upside: +67.41%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.55
Upside: +135.29%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $7.47
Upside: +87.42%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $15.49
Upside: +35.62%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $28.16
Upside: -82.24%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $1.99
Upside: +302.01%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $13.38
Upside: +565.17%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $11.50
Upside: +943.48%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.10
Upside: +9,627.63%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $13.15
Upside: +546.39%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $3.79
Upside: +929.02%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $22.72
Upside: +150.88%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.13
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $0.80
Upside: +112,965.33%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $7.44
Upside: +168.82%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.23
Upside: +42,525.75%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $44.34
Upside: -21.06%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $13.52
Upside: +195.86%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $25.78
Upside: +1,855.38%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $338.06
Upside: -31.96%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $9.59
Upside: +11,630.97%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $0.88
Upside: +4,434.63%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $29.43
Upside: -26.95%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $49.96
Upside: -52.96%